---
id: clinical-trial-recruitment-reform
title: Clinical Trial Outreach and Recruitment Reform
sidebar_label: Trial Recruitment
sidebar_position: 1
slug: /healthcare/pharma/trial-recruitment
tags:
  - healthcare
  - pharmaceuticals
  - clinical-trials
  - recruitment
  - ssi
description: >
  National clinical-trial outreach and recruitment framework to reduce cost,
  delay, and failure risk through a privacy-preserving eligibility discovery
  layer that is patient-controlled and opt-in.
phase: 2

---

## Purpose

This brief defines a national clinical-trial outreach and recruitment framework designed to reduce cost, delay, and failure risk in pharmaceutical R&D—especially for areas of clear public need where private investment underperforms. The scope is limited to recruitment, prescreening, and feasibility discovery. It does not alter safety standards, pricing, IP ownership, or care delivery.

The objective is to replace bespoke, duplicative recruitment processes with a privacy-preserving eligibility discovery layer that is patient-controlled, opt-in, and infrastructure-based.

## Problem Statement

Clinical trials routinely fail or delay due to slow and uncertain patient recruitment. Current systems rely on fragmented site networks, manual chart review, advertising, and physician referral. This produces high fixed costs, long timelines, and strong bias toward large, profitable indications. Preventive, nutritional, rare-disease, and low-margin therapeutic areas are systematically underinvested despite strong scientific rationale.

The failure is structural. There is no national mechanism to determine how many eligible patients exist, where they are, or to allow them to discover trials without surrendering privacy or autonomy.

## Design Principles

1. Patient-pull, not sponsor-push.
2. No national disease registry.
3. No continuous monitoring or surveillance.
4. Opt-in, revocable consent at every stage.
5. Minimal disclosure using cryptographic proofs.
6. Public standards, multiple private implementations.

## Core Mechanism: Eligibility Discovery Layer

### Public Trial Registry

All participating trials publish standardized, machine-readable inclusion and exclusion criteria to a public registry. Criteria are visible to anyone and are not targeted to specific individuals.

### Local Eligibility Matching

Patients use a health wallet built on SSI credentials. The wallet holds verifiable credentials issued through normal care (diagnosis attestations, lab-range bands, medication exposure flags, demographic bands).

Eligibility matching occurs locally on the patient’s device or trusted enclave. No data is transmitted during browsing or sorting. The system produces no outbound signal unless the patient initiates contact.

### Optional Aggregate Feasibility Counts

Patients may opt in to anonymous feasibility aggregation. Devices contribute encrypted yes/no signals for specific trials into secure aggregation protocols. Sponsors see counts only, with no link to individuals.

Participation in aggregation is optional and not required for browsing or enrollment.

## Consent Gates

The framework enforces three explicit consent stages:

1. **Matching Opt-In**: Patient authorizes local trial matching only. No data leaves the device.
2. **Eligibility Proof Opt-In**: Patient chooses a trial and authorizes generation of minimal cryptographic proofs (e.g., eligibility satisfied) and a contact relay.
3. **Clinical Enrollment**: Traditional informed consent and medical record access under existing regulations.

Each gate is independent and revocable.

## Information Shared at Each Stage

**Stage 1 – Matching**
- Nothing shared externally.

**Stage 2 – Prescreening**
- Contact relay (not direct identity)
- Binary eligibility proofs (yes/no flags)
- Only credentials explicitly approved by the patient

**Stage 3 – Enrollment**
- Standard disclosures under current clinical trial law

## Scope of Use

This framework applies to:
- Pharmaceutical and biologic trials
- Nutrition and prevention studies
- Rare disease research
- Public health pilots

It does not mandate use. Sponsors may continue to recruit through existing CROs, hospital networks, or private channels.

## Safeguards

- No centralized health database
- No sponsor access to raw patient data
- Time-bounded, purpose-limited credentials
- Independent audits of aggregation and consent flows
- Public dashboards showing utilization and outcomes

## Expected Impact

- Reduced time-to-first-patient
- Lower recruitment failure rates
- Viable trials in public-need areas
- Reduced reliance on advertising and site congestion
- Improved patient agency and access

## Relationship to Other Pharma R&D Components

This brief integrates with:
- Regional Clinical Trial Infrastructure (execution capacity)
- Modular Therapeutic Manufacturing Facilities (CMC risk reduction)

Together, these form a bounded R&D de-risking stack without altering market pricing or IP incentives.

## Pilot Path

Initial pilots should focus on one or two therapeutic areas with high public value and recruitment challenges, such as nutrition/metabolic disease or antibiotics. Metrics include enrollment speed, cost per enrolled patient, and participant retention.